Abstract N6-methyladenosine (m 6 A) RNA methylation is the most abundant form of mRNA
modification in eukaryotes and is at the front line of biological and biomedical research. This …

Small RNAs (also referred to as small noncoding RNAs, sncRNA) are defined as polymeric
ribonucleic acid molecules that are less than 200 nucleotides in length and serve a variety of …

Background METTL3 is the core catalytic enzyme in m6A and is involved in a variety of
cardiovascular diseases. However, whether and how METTL3 plays a role during …

RNA is not always a faithful copy of DNA. Advances in tools enabling the interrogation of the
exact RNA sequence have permitted revision of how genetic information is transferred. We …

Objective Myocardial ischemia/reperfusion (MI/R) injury is a complicated pathophysiological
process associated with cardiomyocyte pyroptosis. Methyltransferase-like protein 3 …

N6-methyladenosine (m6A) modification is the most universal and abundant post-
transcriptional modification of eukaryotic RNA and occurs mainly at the consensus motif RR …

Cardiovascular disease (CVD) is the leading cause of death in the world, with a high
incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable …

Rheumatoid arthritis (RA), one of the most common autoimmune diseases, is characterized
by immune cell infiltration, fibroblast-like synovial cell hyperproliferation, and cartilage and …

M6A modification is an RNA-important processing event mediated by methyltransferases
METTL3 and METTL14 and the demethylases. M6A dynamic changes after myocardial …

Recent studies have identified that N6-methyladenosine (m6A) extensively participates in
the myocardial injury pathophysiological process. However, the role of m6A on sepsis …